Xenetic Biosciences (XBIO) Proxy Filing summary

Executive summary

• The annual meeting was adjourned due to lack of quorum and will reconvene virtually on January 8, 2026, to allow more time for proxy solicitation.

• Stockholders as of October 15, 2025, are eligible to vote, and previously submitted proxies remain valid unless revoked.

• The company is focused on advancing immuno-oncology technologies, particularly its DNase platform targeting neutrophil extracellular traps in cancer.

• Forward-looking statements highlight plans to advance the systemic DNase program into clinical trials for pancreatic carcinoma and other solid tumors.

Voting matters and shareholder proposals

• No changes have been made to the proposals to be voted on at the reconvened annual meeting.

• Stockholders are urged to review the definitive proxy statement and vote by January 7, 2026.

Risk oversight and compliance

• Forward-looking statements are subject to risks including unexpected costs, uncertainty in financial performance, and the outcome of ongoing strategic reviews.

• Additional risks include market, regulatory, and geopolitical factors, as well as potential impacts from shareholder activism.